Management of chronic hepatitis C virus infection: A consensus report of the study group for viral hepatitis of the Turkish society of clinical microbiology and infectious diseases-2017 update

Basit Öğe Kaydı
dc.contributor.authorAygen, Bilgehan
dc.contributor.authorDemirtürk, Neşe
dc.contributor.authorTürker, Nesrin
dc.contributor.authorAsan, Ali
dc.contributor.authorEraksoy, Haluk
dc.contributor.authorGürbüz, Yunus
dc.contributor.authorİnan, Dilara
dc.date.accessioned2025-01-27T19:00:50Z
dc.date.available2025-01-27T19:00:50Z
dc.date.issued2017
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractPreviously a consensus report about management of hepatitis C virus (HCV) infection, a major health problem all over the world had been prepared by Study Group for Viral Hepatitis of the Turkish Society of Clinical Microbiology and Infectious Diseases. It was first published in the Klimik Journal in 2014. Recently, we needed to update this report considering the new developments in treatment of chronic hepatitis C (CHC). This new consensus report is based on review of current literature and international guidelines. Agreed recommendations are presented at the end of each section such as epidemiology and natural history of HCV infection, diagnosis of acute hepatitis C (AHC) and CHC, treatment of AHC, goals of CHC therapy and pre-therapeutic assessment of CHC therapy, indications for treatment, contraindications to therapy, direct-acting antivirals (DAA) in the treatment of CHC and drug-drug interactions in the treatment of DAA, resistance problem in DAA treatment and clinical assesment of resistance, monitoring and managing treatment safety and side effects, post-treatment follow-up of patients who achieve a sustained virological response (SVR), follow-up of patients who didn’t achieve an SVR and prevention of HCV infection. © 2017, AVES Ibrahim Kara. All rights reserved.
dc.identifier.doi10.5152/kd.2017.12
dc.identifier.endpage35
dc.identifier.issn1301-143X
dc.identifier.issueSpecial Issue 1
dc.identifier.scopus2-s2.0-85027843841
dc.identifier.scopusqualityQ4
dc.identifier.startpage2
dc.identifier.urihttps://doi.org/10.5152/kd.2017.12
dc.identifier.urihttps://hdl.handle.net/20.500.12428/13475
dc.identifier.volume30
dc.indekslendigikaynakScopus
dc.language.isotr
dc.publisherAVES Ibrahim Kara
dc.relation.ispartofKlimik Dergisi
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_Scopus_20250125
dc.subjectAntiviral agents; Chronic hepatitis C; Therapy
dc.titleManagement of chronic hepatitis C virus infection: A consensus report of the study group for viral hepatitis of the Turkish society of clinical microbiology and infectious diseases-2017 update
dc.title.alternativeKronik hepatit C virusu infeksiyonunun yönetimi: Türk klinik mikrobiyoloji ve infeksiyon hastaliklari derneği viral hepatit çalişma grubu uzlaşi raporu-2017 güncellemesi
dc.typeArticle

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu